{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-23-000077","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.466287+00:00","generated_at":"2026-06-13T00:51:00.015471+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Maravai LifeSciences completes planned CEO succession; Martin becomes CEO, Hull Executive Chairman","bullets":["William 'Trey' Martin, III named CEO effective July 27, 2023; previously President of Biologics Safety Testing segment.","Carl Hull transitions from interim CEO to Executive Chairman; annual base salary reduced to $500,000.","Hull's target annual bonus set at 100% of salary for 2024+; 2023 target remains $757,667.","Martin's compensation unchanged from his prior role as President of Biologics Safety Testing."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-23-000077","json":"https://secwatch.observer/filing/0001823239-23-000077.json","markdown":"https://secwatch.observer/filing/0001823239-23-000077.md","text":"https://secwatch.observer/filing/0001823239-23-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000077/0001823239-23-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000077/mrvi-20230727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T00:51:00.015471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19e59d9ef5","claim":"William 'Trey' Martin, III was appointed as Chief Executive Officer at MARAVAI LIFESCIENCES HOLDINGS, INC..","evidence_excerpt":"On July 27, 2023, William “Trey” Martin, III assumed the role of Chief Executive Officer (“CEO”) of Maravai LifeSciences Holdings, Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000077/0001823239-23-000077-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assumed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"7a60be2adb","claim":"Carl W. Hull changed role as Executive Chairman at MARAVAI LIFESCIENCES HOLDINGS, INC..","evidence_excerpt":"Concurrently with the appointment of Mr. Martin as CEO, Carl W. Hull ceased to serve as interim CEO of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000077/0001823239-23-000077-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}